Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 10/20 | 0.46 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937190 | 0.82 | ALDH1A1 (0.69) | ALDH1A1EPHX2PDK1PDK2PDK3 | |
| SCHEMBL5391493 | 0.79 | KDM1A (0.67) | KDM1A | |
| SCHEMBL4636574 | 0.79 | PKM (0.56) | ALDH1A1KCNA5 | |
| SCHEMBL4635518 | 0.79 | HSD17B10 (0.52) | ALDH1A1CA1CA2 | |
| SCHEMBL4635076 | 0.79 | HSD11B1 (0.46) | ALDH1A1 | |
| SCHEMBL4635067 | 0.79 | HSD11B1 (0.51) | ALDH1A1PAX8CA1CA2 | |
| SCHEMBL10215017 | 0.78 | KDM1A (0.66) | ALDH1A1EPHX2PDK1PDK2PDK3 | |
| SCHEMBL17319228 | 0.78 | ALDH1A1 (1.00) | ALDH1A1EPHX2PDK1PDK2PDK3 | |
| SCHEMBL21485438 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KCNA5EPHX2PDK1PDK2 | |
| SCHEMBL4892280 | 0.78 | NAMPT (0.58) | EPHX2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | ALDH1A1 891/4885KCNA5 700/4885EPHX2 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.